All In Biotech

Drug Trial Radar · NCT07741981

Treatment Resistance in Psychiatric Disorders: the Search for Biological Markers Predictive of Response to Treatment

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Aug 20, 2026

Primary completion

Nov 1, 2036

Study completion Sep 1, 2038

Sponsor

Lead sponsor
Centre Hospitalier St AnneAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
GHU Paris Psychiatry & Neurosciences
First posted
Aug 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The disruption of immune system is a key candidate in the pathogenesis of psychiatric disorders, especially those resistant to traditional treatments. Involving complex processes within the brain and peripheral immune system, inflammation may lead to imbalance of neurotransmitter systems and synaptic plasticity and directly contribute to the psychiatric symptoms observed in conditions such as depression, bipolar disorder (BD) and schizophrenia (SCZ). Studies show that treatment-resistant depression (TRD) is associated with elevated levels of inflammatory markers in the blood, which are linked to a lower response to conventional antidepressants. Interventions that modulate this inflammatory response, such as immunomodulatory treatments or therapies targeting pro-inflammatory cytokines, have demonstrated beneficial effects by reducing symptoms and improving patients' quality of life. A thorough understanding of the links between inflammation and treatment resistance therefore paves the way for innovative therapeutic strategies. These approaches could transform current practices by offering more personalized and effective solutions for patients suffering from chronic and resistant psychiatric disorders.

Conditions

  • Schizophrenia
  • Treatment Resistant Depression (TRD)
  • Bipolar Disorder (BD)
  • Catatonia
  • Obsessive Compulsive Disorder (OCD)

Interventions

  • Blood sampling, lumbar puncture, stool sampling, skin microbiopsy and psychometrics scalesBiological

    the biomarker research involves different biological sampling : blood, stool, cerebrospinal fluid, skin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3)Time frame: Up to 10 weeks
  2. Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3)Time frame: Up to 10 weeks
  3. Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3)Time frame: Up to 10 weeks
  4. Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3)Time frame: Up to 10 weeks
  5. Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3)Time frame: Up to 10 weeks
  6. Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3)Time frame: Up to 10 weeks
  7. Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3).Time frame: Up to 10 weeks
  8. Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3).Time frame: Up to 10 weeks
  9. Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3).Time frame: Up to 10 weeks
  10. Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3).Time frame: Up to 10 weeks
  11. Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3).Time frame: Up to 10 weeks
  12. Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3).Time frame: Up to 10 weeks
  13. Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3).Time frame: Up to 10 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GHU Paris - Psychiatrie et Neurosciences

    Paris, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.